Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2020 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

REDWOOD CITY, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for...
November 13, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results

REDWOOD CITY, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
October 25, 2019 16:30 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock

REDWOOD CITY, Calif., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
October 23, 2019 09:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock

REDWOOD CITY, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
October 22, 2019 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
October 02, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
September 24, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
September 19, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

REDWOOD CITY, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
August 07, 2019 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results

REDWOOD CITY, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
July 25, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome

REDWOOD CITY, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for...